Sponsored content

Novel anti-inflammatory compounds for psoriasis and beyond

Anatabine citrate, a cholinergic small molecule in development at Rock Creek Pharmaceuticals, offers a distinct alternative to existing nonsteroidal anti-inflammatory drugs (NSAIDs), steroids and biologics for the treatment of chronic and acute inflammatory diseases. The company is looking to partner for a phase 2 trial in psoriasis. To download the full article, please sign in.

Upvote 1 Comment
Page of
Go to the profile of Rock Creek Pharmaceuticals, Inc.

Rock Creek Pharmaceuticals, Inc.

Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic and acute inflammatory diseases. Rock Creek Pharmaceuticals’ compound is a small molecule, cholinergic agonist that exhibits anti-inflammatory pharmacological characteristics, distinct from other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The Company’s lead compound has been investigated extensively in pre-clinical (in vitro and in vivo) studies resulting in several peer reviewed and published scientific journal articles, covering models of multiple sclerosis, Alzheimer's disease, and autoimmune thyroiditis. All these studies demonstrated the anti-inflammatory effects of the Company’s compound. In addition, the Company's compilation of human exposure, safety and tolerability data, has provided important insights for ongoing clinical and regulatory pharmaceutical development.
0 Contributions
5 Followers
0 Following

Please sign in or register for FREE to comment